Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study

  • GRELL EUROCARE-5 Working Group
  • Department of Preventive and Predictive Medicine
  • IRCCS Fondazione Don Carlo Gnocchi - Milano
  • Public Health Division of Gipuzkoa
  • Spain and CIBER of Epidemiology and Public Health (CIBERESP)
  • Catalan Institute of Oncology (ICO)
  • SOC Epidemiologia e Biostatistica
  • IRCCS Centro di Riferimento Oncologico
  • Belgian Cancer Registry
  • Department of surgical urology
  • Austrian CR
  • Tyrol CR
  • Belgian CR
  • Bulgarian CR
  • Croatian CR
  • Czech National CR
  • Danish Cancer Society
  • Estonian CR
  • Tallinn University of Technology
  • Finnish CR
  • Bas Rhin CR
  • Basse Normandie Haematological malignancies CR
  • Calvados Digestive Tract Registry
  • Calvados
  • Côte d'Or Digestive Tract Registry
  • Côte d’Or Gynaecologic CR
  • Côte d’Or Haematological Malignancies CR
  • Doubs CR
  • Finistère Digestive Tract Registry
  • Gironde CNS CR
  • Gironde Haematological Malignancies CR
  • Hérault CR
  • Hospices Civils de Lyon
  • Isere Cancer Registry (Grenoble)
  • Loire-Atlantique CR
  • Manche CR
  • MSA Marne Ardennes Meuse
  • Somme CR
  • Tarn CR
  • Bavaria CR
  • Berlin CR

Abstract

Background We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. Methods The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000-2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999-2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. Results We analysed 1,021,275 male genital cancer cases. Five-year relative survival was high and decreased with increasing age for all tumours considered. We found limited variation in survival between European regions with Eastern Europe countries having lower survival than the others. Survival for penile cancer patients did not improve from 1999 to 2007. Survival for testicular cancer patients remained stable at high levels since 1999. Survival for prostate cancer patients increased over time. Conclusions Treatment standardisation and centralisation for very rare diseases such as penile cancers or advanced testicular tumours should be supported. The high survival of testicular cancer makes long-term monitoring of testicular cancer survivors necessary and CRs can be an important resource. Prostate cancer patients' survival must be interpreted considering incidence and mortality data. The follow-up of the European Randomised Study of Screening for Prostate Cancer should continue to clarify the impact of screening on prostate cancer mortality together with population based studies including information on stage and treatments.

OriginalspracheEnglisch
ZeitschriftEuropean Journal of Cancer
Jahrgang51
Ausgabenummer15
Seiten (von - bis)2206-2216
Seitenumfang11
ISSN0959-8049
DOIs
PublikationsstatusVeröffentlicht - 01.10.2015

Fördermittel

The Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No 20102202). The study was funded by the Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No 20102202). The funding sources had no role in study design, the collection, analysis or interpretation of data, the writing of the report, or the decision to submit the article for publication.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Fingerprint

Untersuchen Sie die Forschungsthemen von „Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren